Highest-materiality recent filing
Pelthos Therapeutics CEO to present at Jefferies conference; no material news disclosed
CEO Scott Plesha will present at 11:05 a.m. ET on June 4, 2026 at the Jefferies Global Healthcare Conference in New York.
Pelthos Therapeutics dismisses CFO Knuettel, appoints Grant Thornton as auditor
CFO Francis Knuettel II terminated effective April 10, 2026; separation agreement provides $430,000 severance (12 months salary) and accelerated vesting of 59,500 options and 19,525 RSUs.
Pelthos Therapeutics Q1 2026 ZELSUVMI net revenue $10.7M, up 17% QoQ; net loss $10.2M
ZELSUVMI net product revenue $10.7M in Q1 2026, up 17% from $9.1M in Q4 2025; units dispensed 7,884 (+25% QoQ).
CEO Scott Plesha to attend Piper Sandler Spring Biopharma Symposium on April 16, 2026
CEO will hold one-on-one investor meetings at conference in Boston.
Pelthos Therapeutics appoints John M. Gay as CFO, replaces Francis Knuettel II
John M. Gay appointed CFO effective April 10, 2026; also named treasurer and secretary.
Pelthos Q4 ZELSUVMI sales $9.1M, up 28% QoQ; adds XEPI and XEGLYZE
ZELSUVMI net product revenue $9.1M in Q4 2025 vs $7.1M in Q3; full-year 2025 total revenue $16.8M.
Pelthos secures up to $50M senior secured term loan from Horizon; $30M drawn at close
Up to $50M senior secured term loan facility from Horizon Technology Finance; $30M funded at closing on Jan 12, 2026.
Non-Executive Chairman annual cash retainer increased from $50k to $60k, effective January 1, 2026.
Pelthos Therapeutics acquires Xeglyze (abametapir) head lice treatment for $1.8M
Total purchase price $1.8M; $450K deposit paid Nov 20, 2025, $1.35M paid at closing Dec 23, 2025.
Pelthos Therapeutics appoints Andrew Einhorn to Board of Directors; board expands to eight
Andrew Einhorn appointed to Board effective December 23, 2025, filling newly created eighth seat.
All seven director nominees elected with >2.24M 'For' votes each; broker non-votes of 278,134.
Pelthos Q3: ZELSUVMI launch generates $7.1M net revenue, net loss $16.2M
Net product revenue of $7.1M from ZELSUVMI in first commercial quarter (Q3 ended Sep 30, 2025).
Pelthos raises $18M via convertible notes; acquires Xepi from Biofrontera
Issued $18.0M aggregate 8.5% senior secured convertible notes due Nov 2027; conversion price $34.442/sh (adjustable to $29.73 on shareholder approval).
Pelthos Therapeutics posts corporate presentation; no specific material updates disclosed
Corporate presentation for Q4 2025 made available on company website on October 14, 2025.
Pelthos (PTHS) files LNHC unaudited financials and pro forma data post-merger closed July 1, 2025
Merger closed July 1, 2025; issued ~31,278 Series A Preferred shares to Ligand; PIPE raised ~$50.1M gross.
Pelthos Therapeutics to present at Wells Fargo 2025 Healthcare Conference on Sept 3
CEO Scott Plesha and CFO Frank Knuettel to present at Wells Fargo Healthcare Conference on Sept 3, 2025 at 1:30 pm ET.
Pelthos Therapeutics completes merger, launches ZELSUVMI, hires 50 sales managers
Completed merger with Channel Therapeutics and closed $50.1M private placement on July 1, 2025.
Pelthos Therapeutics closes merger with LNHC, raises $50.1M PIPE
Closed merger with LNHC (Ligand subsidiary) on July 1, 2025; LNHC shareholders own ~55.8% on fully diluted basis.
Channel Therapeutics issues NYSE American-required announcement on going concern in 2024 10-K
2024 10-K audit opinion includes a going concern emphasis of matter (previously filed March 27, 2025).
Channel Therapeutics to merge with LNHC in reverse merger; Ligand to own ~55%
LNHC valued at $67M; Channel at $15M; combined entity renamed Pelthos Therapeutics Inc.
Channel Therapeutics issues $325K promissory note to 3i, L.P. at $250K purchase price
Issued $325,000 principal unsecured note to 3i, L.P. for $250,000 purchase price (approx. 23% discount).
Chromocell renamed Channel Therapeutics, reincorporates in Nevada; pipeline milestones expected soon
Name change to Channel Therapeutics effective Nov 18, 2024; reincorporation in Nevada for lower taxes and strategic flexibility.
Channel Therapeutics completes reincorporation from Delaware to Nevada; stockholder rights change
Chromocell Therapeutics merged into wholly-owned Nevada subsidiary Channel Therapeutics; all shares converted 1:1.
Chromocell reincorporates as Nevada corporation Channel Therapeutics; shares convert 1:1
On Nov 18, 2024, Chromocell Therapeutics (Delaware) merged into its Nevada subsidiary, Channel Therapeutics Corp, as the surviving entity.
Proposal 4 approved: reincorporation from Delaware to Nevada and renaming to Channel Therapeutics Corp. (2.6M for, 2.3K against, 929.7K abstain).
Chromocell authorizes $250K stock repurchase plan; up to ~23% of non-affiliate float
Authorized repurchase of up to $250,000 of common stock, representing ~23% of non-affiliate float.
Chromocell raises $750k via convertible note and secures $30M committed equity facility
$750k convertible note issued, 6% interest (12% default), convertible at $1.506/share, floor $0.231, maturity Aug 24, 2025.
the Board terminated Francis Knuettel II from his position as Chief Financial Officer, Treasurer and Secretary of the Company, effective April 10, 2026.
Max materiality 1.00 · Median 0.55 · Most common event other_material